Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UTOPIA: Tofogliflozin and Atherosclerosis in Type 2 Diabetes
jRCTs051180031Completed
- Sponsor
- Kowa Company, Ltd.
- Start
- Jan 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised trial of tofogliflozin in type 2 diabetes mellitus (T2DM) and atherosclerosis (2 arms), sponsored by Kowa Company, Ltd. Primary endpoint: Change in carotid IMT (mean and max). Started Jan 2016; status: completed.
02
Drugs
tofogliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)atherosclerosis
Beyond the preview
Go deeper on jRCTs051180031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051180031.